Anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF), approved by the U.S. Food and Drug Administration (FDA), represent a major breakthrough in the therapy of diabetic retinopathy (DR) [1]. The gene discussed is VEGFA; the disease is diabetic retinopathy.